Clinical trial
Transurethral Resection and Combination Chemotherapy in Treating Patients With…
NCT00003640 · European Organisation for Research and Treatment of Cancer - EORTC, Other · Terminated
Key facts
| NCT number | NCT00003640 |
|---|---|
| Title | Transurethral Resection and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer |
| Official title | A Feasibility Study of Thorough Transurethral Resection (TURB) and Escalated Dose M-VAC Chemotherapy as Primary Treatment of T2-T3a, N0-Nx, M0 Transitional Cell Carcinoma of the Bladder, With the Intention of Bladder Preservation |
| Lead sponsor | European Organisation for Research and Treatment of Cancer - EORTC, Other |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Bladder Cancer |
| Intervention type | Biological, Drug, Procedure, Radiation |
| Interventions | filgrastim, cisplatin, doxorubicin hydrochloride, methotrexate, vinblastine sulfate, surgical procedure, radiation therapy |
| Enrollment | 73 |
| Start date | Sep 1, 1998 |
| Primary completion | Nov 1, 2000 |
| First posted | May 20, 2004 |
| Last update posted | Mar 6, 2012 |
| Countries | Italy |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: